Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the nationwide commercial launch of three new cancer diagnostic products: ProOnc TumorSourceDx, ProOnc SquamousDx and ProOnc MesotheliomaDx. Each of these tests is based on recently developed, highly sensitive microRNA technology.